Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−6.4169 EUR
−55.47 M EUR
6.49 M EUR
3.53 M
About Assembly Biosciences, Inc.
Sector
CEO
Jason A. Okazaki
Headquarters
South San Francisco
Website
Founded
2005
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on LS exchange Assembly Biosciences, Inc. stocks are traded under the ticker A402CB.
A402CB stock has risen by 0.36% compared to the previous week, the month change is a 0.36% rise, over the last year Assembly Biosciences, Inc. has showed a 0.36% increase.
We've gathered analysts' opinions on Assembly Biosciences, Inc. future price: according to them, A402CB price has a max estimate of 34.54 EUR and a min estimate of 34.54 EUR. Watch A402CB chart and read a more detailed Assembly Biosciences, Inc. stock forecast: see what analysts think of Assembly Biosciences, Inc. and suggest that you do with its stocks.
A402CB stock is 0.36% volatile and has beta coefficient of 1.14. Track Assembly Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Assembly Biosciences, Inc. there?
Yes, you can track Assembly Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Assembly Biosciences, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
A402CB earnings for the last quarter are −1.36 EUR per share, whereas the estimation was −2.07 EUR resulting in a 34.44% surprise. The estimated earnings for the next quarter are −1.73 EUR per share. See more details about Assembly Biosciences, Inc. earnings.
Assembly Biosciences, Inc. revenue for the last quarter amounts to 6.15 M EUR, despite the estimated figure of 5.18 M EUR. In the next quarter, revenue is expected to reach 3.43 M EUR.
A402CB net income for the last quarter is −8.63 M EUR, while the quarter before that showed −10.41 M EUR of net income which accounts for 17.07% change. Track more Assembly Biosciences, Inc. financial stats to get the full picture.
No, A402CB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 16, 2025, the company has 65.00 employees. See our rating of the largest employees — is Assembly Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Assembly Biosciences, Inc. EBITDA is −41.55 M EUR, and current EBITDA margin is −896.22%. See more stats in Assembly Biosciences, Inc. financial statements.
Like other stocks, A402CB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Assembly Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.